▲ +115.69% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Global Blood Therapeutics in the last 3 months. The average price target is $93.82, with a high forecast of $152.00 and a low forecast of $45.00. The average price target represents a 115.69% upside from the last price of $43.50.
The current consensus among 17 investment analysts is to buy stock in Global Blood Therapeutics. This Buy consensus rating has held steady for over two years.
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.